1y ago: The launch of the Anti-Cancer Therapy Research
Theralase launches Anti-Cancer Therapy Research Centre
Toronto, Ontario – March 29, 2021
located within the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Unity Health Toronto, effective April 1, 2022, relocating its research team from University Health Network (“UHN”), Toronto.
The Li Ka Shing Knowledge Institute of St. Michael’s is home to leading researchers, educators and clinicians — dedicated professionals making new scientific discoveries, generating novel therapies, developing innovative training programs and helping translate knowledge into practice.
The ACT research centre is a fully equipped laboratory dedicated exclusively to Theralase® ACT research and development as it advances towards commercialization with its lead PDC, TLD-1433, as well as its systemic and targeted formulation – Rutherrin®. A Partnership with the Li Ka Shing Knowledge Institute of Unity Health provides access to additional expertise, advisory networks and opportunities to accelerate product development and commercialization.
__________________
This research center has been created for very strategic reasons, one year ago. They wouldn't have created this just for fun, without knowing they can go commercial with PDT/PDC. In the meantime, they had to let the Ph. 2b trial continue to proceed and allow data to be collected. COVID-19 has slowed things a bit, but enrollment continues.
So this Anti-Cancer Therapy Research, within the institute of a billionnaire is there to offer continuity, bring this to mainstream and bedside and allow our full valuation. There's no other reason.
Not sure the April 1, 2022 was a typo or not but it doesn't matter much. What matters is that they planned the next move and this next move is commercialization.
Not a big pharma has the luxury (over competitors) to ignore such a market dominance if our %CR and %DR are above anything else on the market as this would mean total dominance of the bladder market for years. BCG, with poor efficacy results, many treatments and 50%+ recurrence rate, has been able to dominate for 40 years simply because of lack of R&D investments in the bladder indication. So if we hit 50%+, don't think that, all of a sudden, some will start investing in NMIBC R&D. So we<ll be there for a while (2054).
PDT/PDC gainst NMIBC destroys instantly, with no side effects, with 2 doses, and could be repeated, if needed!
The FDA will not ignore that, especially when it can help delay cystectomy for few months. Or better than that; simply avoid it and save a bladder.
We've seen many treatments receiving Breakthrough designation just for few additional months of survival benefits. TLT's technology has the ability to save bladders, avoid 6-7 hour life-threatening surgeries, restore quality of life (QOL), an important indicator that all specialists always look at.
Such stand-alone treatment is worth B$$$. If we reconfirm our efficacy ratios, not only urologists will have jaw-dropping reactions but also all the oncology industry. And we have other PDCs in our portfolios, on top of Rutherrin and TLD-1433.